drugset / Trial / NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
Timeline
- Start
- 2026-04-28
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | — |